AB-FUBINACA 2-fluorobenzyl isomer

Overview

AB-FUBINACA 2-fluorobenzyl isomer is a synthetic cannabinoid that belongs to the indazole-3-carboxamide family. It is a structural isomer of AB-FUBINACA, which was originally developed by Pfizer as a potential analgesic but was never marketed. The 2-fluorobenzyl isomer specifically refers to the substitution of a fluorine atom on the benzyl group, which can significantly alter the compound's pharmacological properties.

Chemical Structure

The chemical structure of AB-FUBINACA 2-fluorobenzyl isomer is characterized by the presence of an indazole core, a carboxamide linkage, and a fluorinated benzyl group. The molecular formula is C21H22FN3O2, and it has a molecular weight of 367.42 g/mol. The presence of the fluorine atom in the benzyl group distinguishes it from other isomers and analogs.

Pharmacology

AB-FUBINACA 2-fluorobenzyl isomer acts as a potent agonist of the cannabinoid receptors, primarily CB1 and CB2. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including mood, appetite, and pain sensation. The fluorine substitution can affect the binding affinity and efficacy of the compound at these receptors, potentially leading to differences in potency and duration of action compared to non-fluorinated analogs.

Legal Status

The legal status of AB-FUBINACA 2-fluorobenzyl isomer varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids and "designer drugs."

Health Effects and Risks

The use of AB-FUBINACA 2-fluorobenzyl isomer can lead to a range of effects, including euphoria, altered perception, and relaxation. However, it can also cause adverse effects such as anxiety, paranoia, tachycardia, and in severe cases, psychosis or seizures. The variability in potency and purity of synthetic cannabinoids increases the risk of overdose and toxic reactions.

Research and Development

Research on AB-FUBINACA 2-fluorobenzyl isomer is limited, primarily due to its classification as a controlled substance. However, studies on similar compounds suggest that modifications to the benzyl group, such as fluorination, can significantly impact the pharmacokinetic and pharmacodynamic properties of these molecules.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• AB-FUBINACA
• Designer drugs
• Indazole